The development of new or direct oral anticoagulants was triggered by the disadvantages
of classic oral anticoagulation, which was isolated in Link’s laboratory in 1940. Some of these
limitations are the individual variation in response to these drugs, drug interaction and the need for
regular laboratory monitoring. With increasing comorbidity and life expectancy in populations these
limitations led to interruption of treatment or even underuse of treatment in light of potential side
effects. With the introduction of novel oral anticoagulants some of these drawbacks are targeted
whereas even these drugs also have some limitations and should be given with cautions and not to all patients having an
indication for anticoagulation.
Keywords: Coumadin, novel oral anticoagulation, thrombembolism, warfarin.
Rights & PermissionsPrintExport